Molly Ann Lloyd, NP
Nurse Practitioner · Washington
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- Not verified
- Not the same as out of network.
- Office
- 1
- Since medical school
- 13 years
- Pennsylvania State University College of Medicine, 2013
Offices
1 location · Medstar Medical Group II LLC · 3,726 clinicians in this group
Looking this up.
Hospitals listed: Medstar Georgetown University Hospital. That is not proof they admit you there this week.
Plan participation
Not verified
We could not verify current plan participation for this doctor. This does not mean they are out of network. Call Molly Ann Lloyd’s office at (202) 444-2000 to ask if they take your plan before you enroll.
Hospitals they work in
1 hospital
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Medstar Georgetown University HospitalWashington, DCAcute Care Hospital · Proprietary · Has an emergency department · Birthing-friendlyPart of MedStar Health, which runs 10 hospitals in 2 statesHome of Georgetown Lombardi Comprehensive Cancer Center, a National Cancer Institute designated comprehensive cancer centrePatients rate it 3 of 5 · 72% would definitely recommend itOverall rating: 3 of 5 starsWorse than the national rate — Pressure ulcer rate: 1.26 (0.78 to 1.75) · 7,465 cases, Jul 2022 – Jun 2024Better than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.125, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.391, Oct 2024 – Sep 2025Better than the national rate — SSI - Colon Surgery: 0.179, Oct 2024 – Sep 2025
See every measure and the patient survey for Medstar Georgetown University Hospital
Behind the star rating — Deaths: 0 better, 6 the same, 0 worse of 6 measures. Safety: 3 better, 4 the same, 0 worse of 7 measures. Readmissions: 0 better, 8 the same, 1 worse of 9 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Pressure ulcer rateComplications and deaths | 1.26 (0.78 to 1.75) · 7,465 cases | Worse | Jul 2022 – Jun 2024 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.125 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.391 | Better | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.179 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 0.91 (0.09 to 1.72) · 3,048 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 1.13 (0.9 to 1.36) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 177.6 (140.59 to 214.61) · 263 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for COPD patientsComplications and deaths | 7.7 · 33 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 8.3 · 166 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 11.6 · 250 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 12 · 231 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3.2 · 2,748 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.13 (0 to 0.32) · 8,632 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.27 (0.1 to 0.45) · 9,112 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 4.54 (3.03 to 6.05) · 3,698 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.72 (0.32 to 3.13) · 2,153 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.6 (1.49 to 3.7) · 3,499 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 7.87 (3.27 to 12.46) · 2,168 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 4.06 (1.41 to 6.7) · 2,143 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.37 (0.02 to 2.72) · 1,506 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.6 · 53 cases | None | Apr 2023 – Mar 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.867 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 1.162 | No different | Oct 2024 – Sep 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 21.7 · 227 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -2.3 · 192 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 16.5 · 265 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16 · 302 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.8 (4.5 to 7.4) · 629 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 10 (8.3 to 12.1) · 629 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.5 · 52 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.5 · 54 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 13.1 (10.3 to 16.4) · 2,279 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 1.1 (0.9 to 1.4) · 775 cases | No different | Jan 2024 – Dec 2024 |
What patients said (1,947 patients answered, 17% of those asked)
| Cleanliness | 3 |
| Nurse communication | 3 |
| Doctor communication | 3 |
| Communication about medicines | 2 |
| Discharge information | 3 |
| Overall hospital rating | 3 |
| Quietness | 3 |
| Recommend hospital | 4 |
| Room was "always" clean | 66% |
| Nurses "always" communicated well | 76% |
| Doctors "always" communicated well | 80% |
| Staff "always" explained | 57% |
| Yes, staff "did" give patients this information | 86% |
| Yes, staff "did" give patients information about help after discharge | 85% |
| Doctors "always" explained things so they could understand | 75% |
| Doctors "always" listened carefully | 79% |
| Doctors "always" treated them with courtesy and respect | 86% |
| Patients who gave a rating of "9" or "10" (high) | 69% |
| Staff "always" explained new medications | 72% |
| Nurses "always" explained things so they could understand | 71% |
| Nurses "always" listened carefully | 73% |
| Nurses "always" treated them with courtesy and respect | 84% |
| "Always" quiet at night | 57% |
| "YES", patients would definitely recommend the hospital | 72% |
| Staff "always" explained possible side effects | 42% |
| Yes, staff "did" give patients information about possible symptoms | 88% |
Original Medicare doctor bills
$5,412
Medicare paid this office $5,412 for 23 people. Most of that is long return visits and Botox.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Long return visit (40+ min) | 21 | $5,046 | $97 |
Procedures year by year
| Procedure | 2018 | 2019 | 2020 | 2021 | 2022 | 2024 |
|---|---|---|---|---|---|---|
| Biopsy and aspiration of bone marrow sample for diagnosis | – | – | – | – | 11 | – |
Times billed to Original Medicare each year. A blank year means fewer than 11 people had it, or none: Medicare does not publish smaller counts. Medicare Advantage patients are not included.
Who their Medicare patients are
23 Original Medicare patients in 2024. Average age 66 · 85 and older 0% · Women 52% · Health risk score 3.86. Sicker patients than 9 in 10 peers; the typical nurse practitioner clinician is at 1.42.
Conditions among them: High blood pressure 75% · Chronic kidney disease 52%.
The office billed $20,371, Medicare allowed $7,430 and paid $5,412; for 59 services of 3 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 23 | 59 | 66 | 3.86 | $20,371 | $5,412 |
| 2022 | 23 | 65 | 72 | 4.07 | $20,629 | $5,650 |
| 2021 | 27 | 45 | 71 | 2.49 | $11,688 | $4,369 |
| 2020 | 32 | 69 | 69 | 4.14 | $61,325 | $5,585 |
| 2019 | 20 | 26 | 68 | 4.02 | $19,878 | $2,047 |
| 2018 | 15 | 23 | 64 | 2.52 | $15,248 | $1,376 |
| 2017 | 21 | 39 | 68 | 2.95 | $29,003 | $2,036 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2022: 2 services
| Long return visit (40+ min) | 14 | $4,709 | $107 |
| Biopsy and aspiration of bone marrow sample for diagnosis | 11 | $648 | $59 |
2021: 1 service
| Return visit (30+ min) | 17 | $2,435 | $101 |
2020: 1 service
| Long return visit (40+ min) | 25 | $4,919 | $88 |
2018: 1 service
| Return visit (30+ min) | 13 | $1,201 | $60 |
2017: 1 service
| Return visit (30+ min) | 16 | $1,499 | $60 |
Drugs they prescribed that Part D paid
$728,226
Pharmacies billed $728,226 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
418 generic and 59 brand-name prescriptions · $728,226 in drug cost · 55 antibiotic prescriptions to 13 people.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Jakafi | 34 | $468,270 | $13,773 |
| Xarelto | 18 | $17,334 | $963 |
| Posaconazole | 11 | $12,241 | $1,113 |
| Valacyclovir | 57 | $3,340 | $59 |
| Fluconazole | 14 | $1,192 | $85 |
See all 15 drugs
| Jakafi | 34 | $468,270 | $13,773 |
| Xarelto | 18 | $17,334 | $963 |
| Posaconazole | 11 | $12,241 | $1,113 |
| Valacyclovir | 57 | $3,340 | $59 |
| Fluconazole | 14 | $1,192 | $85 |
| Dexamethasone | 14 | $1,188 | $85 |
| Mirtazapine | 34 | $424 | $12 |
| Nystatin | 15 | $416 | $28 |
| Acyclovir | 13 | $276 | $21 |
| Montelukast | 11 | $177 | $16 |
| Sulfamethoxazole-Trimethoprim | 26 | $165 | $6 |
| Prednisone | 16 | $104 | $6 |
| Duloxetine | 12 | $100 | $8 |
| Pantoprazole | 16 | $96 | $6 |
| Minocycline | 13 | $95 | $7 |
Year by year
| 2024 | 477 | 32 | None | 12% | $728,226 |
| 2023 | 332 | 21 | None | None | $600,728 |
| 2022 | 491 | 23 | 2% (12) | None | $877,122 |
| 2021 | 98 | 23 | None | None | $30,796 |
| 2020 | 184 | 45 | None | 8% | $52,390 |
| 2019 | 201 | 45 | None | None | $31,319 |
| 2018 | 110 | 33 | None | None | $31,431 |
| 2017 | 250 | 52 | 5% (12) | 12% | $53,027 |
| 2016 | 106 | 29 | None | None | $36,650 |
| 2015 | 57 | 15 | None | None | $11,974 |
| 2014 | 73 | 15 | None | None | $15,438 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 7 drugs
| Jakafi | 23 | $356,346 | $15,493 |
| Fluconazole | 13 | $1,989 | $153 |
| Valacyclovir | 19 | $1,722 | $91 |
| Prednisone | 29 | $389 | $13 |
| Montelukast | 13 | $197 | $15 |
| Sulfamethoxazole-Trimethoprim | 20 | $180 | $9 |
| Atorvastatin | 16 | $156 | $10 |
2022: 14 drugs
| Jakafi | 16 | $203,610 | $12,726 |
| Atovaquone | 18 | $10,551 | $586 |
| Xarelto | 13 | $9,582 | $737 |
| Sirolimus | 11 | $4,767 | $433 |
| Valacyclovir | 29 | $3,469 | $120 |
| Fluconazole | 16 | $3,245 | $203 |
| Gabapentin | 32 | $792 | $25 |
| Triamcinolone Acetonide | 13 | $325 | $25 |
| Tamsulosin | 17 | $252 | $15 |
| Pantoprazole | 13 | $241 | $19 |
| Atorvastatin | 25 | $207 | $8 |
| Prednisone | 14 | $195 | $14 |
| Amlodipine Besylate | 17 | $139 | $8 |
| Lisinopril | 12 | $20 | $2 |
2020: 2 drugs
| Atovaquone | 19 | $12,335 | $649 |
| Acyclovir | 39 | $1,021 | $26 |
2019: 3 drugs
| Atovaquone | 11 | $6,143 | $558 |
| Acyclovir | 51 | $1,083 | $21 |
| Sulfamethoxazole-Trimethoprim | 17 | $103 | $6 |
2018: 2 drugs
| Acyclovir | 15 | $444 | $30 |
| Sulfamethoxazole-Trimethoprim | 17 | $162 | $10 |
2017: 6 drugs
| Acyclovir | 17 | $635 | $37 |
| Mycophenolate Mofetil | 12 | $523 | $44 |
| Sulfamethoxazole-Trimethoprim | 19 | $227 | $12 |
| Ondansetron | 12 | $168 | $14 |
| Pantoprazole | 13 | $138 | $11 |
| Prednisone | 12 | $103 | $9 |
2016: 2 drugs
| Acyclovir | 14 | $217 | $16 |
| Sulfamethoxazole-Trimethoprim | 11 | $77 | $7 |
Money from drug and device companies
$725 in 2025
| 2025 | 13 | 26 | None | $725 |
| 2024 | 14 | 34 | None | $946 |
| 2022 | 8 | 9 | None | $372 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Janssen Biotech | Carvykti | $247 | 9 payments
|
| Novartis Pharmaceuticals | Fabhalta | $90 | 3 payments
|
| Takeda Pharmaceuticals U.S.A. | Iclusig | $67 | 2 payments
|
| Incyte | Monjuvi | $54 | 2 payments
|
| Abbvie | Venclexta | $46 | 2 payments
|
| Stemline Therapeutics | Orserdu | $45 | 1 payment
|
See all 26 published payments
| Takeda Pharmaceuticals U.S.A. | Meals · 2025-12-18 | Livtencity | $30 |
| Janssen Biotech | Meals · 2025-12-09 | Darzalex | $26 |
| PharmaEssentia USA | Meals · 2025-12-04 | Besremi | $30 |
| BeOne Medicines USA | Meals · 2025-11-13 | Brukinsa | $26 |
| Janssen Biotech | Meals · 2025-11-06 | Talvey | $22 |
| Stemline Therapeutics | Meals · 2025-10-27 | Orserdu | $45 |
| Takeda Pharmaceuticals U.S.A. | Meals · 2025-10-23 | Iclusig | $37 |
| Syndax Pharmaceuticals | Meals · 2025-10-09 | None | $32 |
| Janssen Biotech | Meals · 2025-10-02 | Carvykti | $30 |
| Janssen Biotech | Meals · 2025-09-25 | Talvey | $39 |
| Janssen Biotech | Meals · 2025-09-18 | Tecvayli | $27 |
| Novartis Pharmaceuticals | Meals · 2025-09-11 | Fabhalta | $32 |
| Janssen Biotech | Meals · 2025-08-28 | Tecvayli | $26 |
| Abbvie | Meals · 2025-08-14 | Venclexta | $25 |
| Regeneron Healthcare Solutions | Meals · 2025-08-07 | Lynozyfic | $22 |
| Geron | Meals · 2025-05-01 | Rytelo | $23 |
| Daiichi Sankyo | Meals · 2025-03-06 | Vanflyta | $23 |
| Novartis Pharmaceuticals | Meals · 2025-02-27 | Fabhalta | $30 |
| Incyte | Meals · 2025-02-13 | Monjuvi | $29 |
| Abbvie | Meals · 2025-02-06 | Venclexta | $21 |
| Novartis Pharmaceuticals | Meals · 2025-02-04 | Scemblix | $28 |
| Janssen Biotech | Meals · 2025-01-28 | Carvykti | $4 |
| Janssen Biotech | Meals · 2025-01-27 | Carvykti | $36 |
| Incyte | Meals · 2025-01-23 | Niktimvo | $25 |
| Astellas Pharma US | Meals · 2025-01-16 | Xospata | $20 |
| Janssen Biotech | Meals · 2025-01-02 | Darzalex | $36 |
See earlier years (2024, 2022)
2024: $946
| Janssen Biotech | Tecvayli | $250 | 10 payments
|
| Takeda Pharmaceuticals U.S.A. | Livtencity | $105 | 2 payments
|
| Novartis Pharmaceuticals | Scemblix | $94 | 4 payments
|
| Incyte | Jakafi | $79 | 3 payments
|
| Sanofi-Aventis U.S. | Rezurock | $71 | 2 payments
|
| Legend Biotech USA | None | $64 | 2 payments
|
| Daiichi Sankyo | Vanflyta | $57 | 2 payments
|
| Genentech USA | Columvi | $53 | 2 payments
|
| Abbvie | Epkinly | $53 | 2 payments
|
| Genzyme | Sarclisa | $37 | 1 payment
|
| Teleflex | Arrow | $30 | 1 payment
|
| GlaxoSmithKline | Ojjaara | $21 | 1 payment
|
| ADC Therapeutics America | None | $19 | 1 payment
|
| Bard Peripheral Vascular | Trek | $15 | 1 payment
|
2022: $372
| Incyte | Jakafi | $124 | 1 payment
|
| E.R. Squibb & Sons L.L.C. | Onureg | $106 | 1 payment
|
| Janssen Biotech | Imbruvica | $45 | 2 payments
|
| Celgene | Onureg | $25 | 1 payment
|
| Pharmacyclics LLC an AbbVie | Imbruvica | $23 | 1 payment
|
| BeiGene USA | Brukinsa | $18 | 1 payment
|
| Seagen | Tukysa | $17 | 1 payment
|
| Novartis Pharmaceuticals | Promacta | $14 | 1 payment
|
Professional record
- NPI
- 1588091300
- Licence
- CA 95002970, DC RN1059249, MD R191205, VA 0024180528
- Trained
- Pennsylvania State University College of Medicine, 2013 · 13 years ago
- Gender
- Female
More record details
- Sole proprietor
- No
- Taxonomy
- Federal specialty code 363LA2100X (363LA2100X)
- Mailing address
- 2150 Pennsylvania Ave Nw, Washington, DC, 20037
- NPI first listed
- 2013-10-11
- NPI last updated
- 2020-12-29
- NPI record certified
- 2020-12-29
This is when the NPI record was last certified, not a medical board exam.
Extra NPI addresses: 300 Pasteur Dr, Stanford, CA, 94305